American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
May 15, 2025
Earnings Call Speaker Segments
Kirin Smith
executiveThank you, Wyatt, and thanks to all of you for being with us today. Earlier this morning, prior to the market opening, AMS released its earnings press release for the first quarter of 2025. Should you require a copy, you can find it on the company's website, www.ashs.com, listed under press releases within the investors tab. Ahead of handing the call to management, I'd like to offer a few comments regarding forward-looking statements. Kindly be aware that any remarks made during this conference call pertaining to future expectations, plans, and prospects for the company are considered forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, owing to a range of important factors, such as those addressed in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2024. No obligation is assumed by the company to update the information in this conference call. Before I hand things over to Ray, I want to remind everybody about our Q&A policy, under which each participant gets the opportunity to ask one question plus one follow-up. As always, we're glad to address further questions offline whenever you like. With that, I'd now like to pass the call to Ray Stachowiak, Executive Chairman. Ray, please go ahead.
Ray Stachowiak
executiveThanks, Kieran, and good afternoon to all of you. We appreciate you being with us today for the conference call covering our earnings for the first quarter of 2025. I'll start things off with a few opening comments, and after that I'll pass things to Gary, our CEO, who will provide more detail, and then Scott Frech, our CFO, will walk through a financial review of what we delivered in quarter one. Once our prepared remarks are finished, we'll take questions from the line. We feel good about the revenue growth we posted in the first quarter of 2025, which came from expansion within our direct patient services segment along with further international business development initiatives. Although treatment volumes did fall during the quarter just ended, the advantages of shifting away from a focus on leasing cancer treatment equipment toward a service model that centers more on patients are plainly starting to show. I'm happy to share that treatment volumes are recovering, and we expect a stronger second half of 2025. During the quarter just reported, revenue grew by double digits, rising 17% compared with the same period a year earlier. That increase came from ongoing gains related to the Rhode Island acquisition we completed last year, plus the launch of our new radiation therapy treatment facility located in Puebla, Mexico. Even as we concentrate on growing revenue, profitability stays a priority for us. Adjusted EBITDA for the first quarter of 2025 reached $949,000, down from $1.75 million in the first quarter of 2024, which reflects lower procedure volume; our cost controls remain strong, with costs that are largely fixed, and we depend on treatment volumes and the count of patients served to fuel top-line growth. Investors need to understand that, in the short term and from one quarter to the next, fluctuations will occur given the particular characteristics of our expanding business, yet looking out over the long term, we are positioned for growth that is both strong and profitable. I encourage investors to keep their eyes on the broader long-term growth opportunity as we carry out our strategic initiatives and reach the milestones ahead of us. In our view, this is a favorable moment for investors to watch our company closely. We genuinely believe we are set up for long-term outperformance as we carry out our growth strategy and strive to build considerable shareholder value. Before handing things over to Gary, I'd also like to call attention to our strong balance sheet, our robust business development pipeline, and the exciting strategic growth opportunities that fuel our enthusiasm and confidence regarding our company's long-term trajectory; with that, I'll turn the call over to Gary Delanois, our CEO, for additional details. Gary.
Gary Delanois
executiveThanks, Ray, and good afternoon to all of you. My belief in and excitement about what we do keeps building, and it's a thrill to steer this company toward its next stage of expansion alongside such a capable leadership group. The advantages we're enjoying keep flowing in from buying the 3 Rhode Island cancer treatment centers along with the more recent one located in Puebla, Mexico. It won't be a smooth, straight line — we do anticipate that treatment volumes will move up and down from quarter to quarter. The growth across the whole business has me energized, and our business development efforts now underway excite me even more. Over at the Rhode Island centers, the upgraded CT simulators for patient treatment planning, plus software improvements that boost efficiency and patient care, are now installed, and we're in a solid position to deliver favorable outcomes over the long term. On top of that, the staffing strategies we implemented please me, and though we haven't yet reached full optimization, the groundwork is laid for rising volumes and utilization that will drive future growth on both the top and bottom lines. Once every one of our Rhode Island centers is fully staffed, I'm certain we'll witness consistent gains in treatment volumes and stronger physician engagement with the healthcare community. What's more, having our linear accelerators covered by service and maintenance agreements boosts their reliability and delivers higher uptime, which means better patient service. Our team keeps concentrating on making our radiation therapy equipment leasing segment stronger by collaborating with health system customers to build greater community awareness among referring physicians, thereby driving more use of their Gamma Knife systems — the gold standard for stereotactic radiosurgery. A substantial growth opportunity remains in our international business segment, where we anticipate sustained momentum. As a reminder, we hold the only Gamma Knife centers in Peru and Ecuador, and through our third international center in Puebla, Mexico, we're treating cancer patients across a full range of cancer diagnoses using the most advanced radiation therapy treatment capabilities available in our catchment area. You'll remember that last year we set up our fourth international center by signing a joint venture agreement for a Gamma Knife center in Guadalajara, Mexico, and we anticipate it will begin treating patients and producing revenue near the end of this year. In a nation of 130 million people, this will be the only S3 Gamma Knife, which plainly offers tremendous value to patients in Mexico and serves as an untapped growth engine for us. Looking ahead over the coming months and years, we anticipate stronger international growth stemming from additional treatment growth in Ecuador, robust volume from our newly upgraded center in Peru, and our two new centers in Guadalajara and Puebla. As Ray said earlier, we keep extending our business footprint in Rhode Island. Buying a 60% controlling stake in the 3 radiation therapy treatment centers located in Rhode Island gave us our initial direct patient services cancer treatment centers within the U.S. This fresh business segment plainly shows how powerful our growth strategy is and goes further in proving we can partner with health systems, Care New England, and Prospect CharterCare, which rank as the second and third largest health systems in Rhode Island. The second item is the Certificate of Need, or CON, that has been awarded to us so we can build and run a fourth radiation therapy center in Bristol, Rhode Island. The third item is a CON we formally secured this past December allowing us to build and operate the state of Rhode Island's first proton beam radiation therapy center, which stands as yet another major growth opportunity; we also have tuck-in acquisitions in the works and expect to close one before this year ends. We look forward to sharing news of further progress on these opportunities as they move ahead. Treatment volumes in cancer care have a tendency to rise and fall periodically because of shifts in diagnosis mix, patient staging, and referring physician consults, and that can produce the lower treatment volumes we saw in the first quarter; during the month of April, we have witnessed significant gains in treatment volumes for Gamma Knife, proton beam radiation therapy, and at the three Rhode Island radiation therapy centers. Before handing the call to Scott, I want to restate how strongly we believe in our overall business. Remember that quarterly fluctuations will occur periodically, as is true for most growth stage companies, but I feel quite optimistic about the strategies we have put in place for our long-term prospects, and I am very excited and honored to work collaboratively with our strong management team to lead the company forward for continued revenue and profitability growth. With that, I'll hand the call to Scott Frech, our CFO, for a financial review.
Scott Frech
executiveThank you, Gary, and good afternoon. For the first quarter that ended March 31, 2025, total revenue rose 17% to $6.1 million, up from $5.2 million in Q1 of 2024. Our direct patient services segment brought in $3.1 million during Q1 2025, versus $963,000 in Q1 2024, which works out to an increase of 224%. That significant growth came mainly from acquiring the Rhode Island radiation therapy operations and starting up operations in Puebla, Mexico, during the second half of 2024. Equipment leasing segment revenue fell to $3 million, down from $4.3 million in Q1 2024. Gamma Knife revenue dropped 18% to $2.1 million for Q1 2025, compared with $2.6 million in Q1 2024. Gamma Knife procedures totaled 208 in Q1 2025, a 24% decrease from the 273 procedures in 2024. That decline stemmed mainly from the expiration of two contracts in December 2024 and February 2025, plus downtime incurred while upgrading a third customer to a new Elekta S3. Proton beam radiation therapy revenue fell 38% to $1.6 million in Q1 2025, versus $2.7 million in Q1 2024. Total proton therapy fractions for Q1 2025 came to 831, a 35% decrease from the 1,276 fractions in Q1 2024; lower volumes were the main reason for this drop. Linear accelerator, or Linac systems, revenue was $2.4 million for Q1 2025, compared with $0 in Q1 of 2024, thanks to the acquisition of the Rhode Island radiation therapy operation and the launch of operations in Puebla, Mexico. Our gross margin for Q1 2025 came in at $942,000, compared with $2.1 million in Q1 2024. The decrease in gross margin and percentage reflects higher operational expenses, increased staffing costs, and investment in technology infrastructure to support growth initiatives, along with lower Gamma Knife treatment volumes and strong growth from our retail patient services segment, which carries a lower gross margin percentage. Q1 2025 operating income was a loss of $1.3 million, compared with a loss of $85,000 in Q1 2024. Net loss attributed to American Shared Hospital Services for Q1 2025 was $625,000, or $0.10 per diluted share, compared with net income of $119,000, or $0.02 per diluted share for Q1 2024. Adjusted EBITDA, our non-GAAP financial measure, was $949,000 for Q1 2025, compared with $1.75 million in Q1 2024. We entered Q1 2025 with a strong financial position supported by our solid balance sheet. As of March 31, 2025, cash and cash equivalents, including restricted cash, stood at $11.5 million, compared with $11.3 million at December 31, 2024. Shareholders' equity, excluding non-controlling interest, was $24.7 million, or $3.82 per outstanding share, compared with $25.2 million, or $3.92 per outstanding share at December 31, 2024. Fully diluted weighted average common shares outstanding were 6,572,000 for Q1 2025 and 6,576,000 for Q1 2024. That wraps up the formal part of our presentation. Thank you again for joining us today. We look forward to updating you on our progress in the quarters ahead. At this point, I want to hand things over to the operator again so we can begin taking your questions.
M. Marin
analystThanks. After going through the press release and considering how fewer procedures being done might matter, there's been quite a bit of discussion recently in the news regarding possible adjustments to certain reimbursement rules. Given some of the conversations we're currently hearing about, does the company think an effect might occur?
Gary Delanois
executiveYes, and I appreciate you asking that. Thanks. What's sort of circulating in Washington and elsewhere amounts to modifications to the Medicaid program specifically. Regarding reimbursements — the rates we get paid — we don't sense we're exposed to a great deal of risk. When it comes to Medicaid, a reduction could happen concerning how many individuals the program covers. Luckily, sizable revenue streams from Medicaid aren't something we have. Private insurers and the Medicare program supply the bulk of our revenue, and our exposure to patients covered under Medicaid is considerably smaller. We don't feel there's a certain level of risk, yet we don't consider that risk to be particularly high.
M. Marin
analystAll right. There's one more thing I wanted to ask about, I think. When you consider the growth projects ahead of you, and one of them involves getting that new facility in Rhode Island up and running — I believe that effort is underway — once another site is operating in Rhode Island, will your ability to handle fixed cost absorption become somewhat more flexible?
Gary Delanois
executiveIndeed. Ours is a business model with substantial fixed costs. Given the direct patient services segment we are moving into and expanding quite considerably, our level of sway and command over the work involved, the connections, and everything capable of helping the patients we treat increase in count is far greater.
M. Marin
analystAlright. Thanks.
Ray Stachowiak
executiveThanks, Wyatt. I appreciate everyone being here with us today. Our company has reached a pivotal moment as we carry out our expansion plan while dealing with certain near-term ups and downs; we're in a strong position operationally and committed to generating solid momentum as that plan gains traction. The purchase in Rhode Island served merely as our initial building block and represented a notable landmark for us. On the global front, moving into Mexico reinforces even more our standing as a frontrunner in specialized radiation therapy services. Substantial potential value lies just ahead of us, as laid out previously. Our certificate of need, or CON, green light in Rhode Island for a fourth radiation therapy center, together with our CON to build and run Rhode Island's first proton beam radiation therapy facility, amounts to enormous long-range chances for additional growth. On top of that, the tuck-in acquisitions currently in progress will likewise assist in boosting our opportunity for expansion even more. We have faith in our approach and in what our team can accomplish. We're eager to bring you up to date on the progress we keep making as we pursue sustainable growth, profitability, and success over the long haul. Should you have any inquiries, please feel free to get in touch. We're happy to have that discussion. Thanks once more for your interest in American Shared Hospital Services. Enjoy the remainder of your day and the remainder of your week. Farewell.
Operator
operatorThat brings this call to a close. We appreciate everyone joining us for today's presentation. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.